Open trial sites consistently and reliably within an average of 90 days, compared to the industry average of 8 months.
Accelerate your clinical trials with unparalleled access to real-world & molecular data.
Captive Audience of 160,000 patients per annum
Large population of Treatment Naive patients
Our establishment has one of the largest pool of treatment naive patients in the world.
Ability to create custom gene panels to support clients need to reduce screening costs
Our state-of-the-art facilities and experienced team enable us to deliver high-quality data at scale, helping to bring innovative treatments to market faster.
50 trial site network, includes cancer centers and hospitals sites.
Led by medical, operational, and regulatory experts experienced in hematology and oncology with deep hematology and oncology experience having managed Phase I-IV trials
Trials network has a captive audience of 160,000 patients annually
Integrated central laboratory services, ensuring seamless logistics, review, and testing
We collaborate with our clients to ensure compliance with the protocol, SOPs, and regulatory guidelines, emphasizing subject safety and data quality/integrity. We deliver a focused and directed risk-based approach to planning and conducting compliance assessments of regulated operations globally by applying the principles of quality risk management (QRM). We oversee the management of quality issues, fostering a culture of continuous process improvement.
Be confident in your data for the entire duration of drug development with responsive and flexible approach to data management and biostatistics. Our Data Management and Biostatistics Team of experts undertake each study with your goal in mind, preparing your data for submission.
Arrant's STARGEN brings end-to-end solutions across phase I-IV of therapeutic development. From discovery research, trial design, and patient enrollment to regulatory approval and post approvals, STARGEN is a full-service affiliate that can tailor solutions to any step of your oncology drug development cycle.
Repertoire of experts with a robust understanding of precision oncology positioned to expedite enrollment and ensure high quality data for sponsors.
Our consortium of StarGen 50 Cancer Centers sites and 250+ Principal Investigators (PI) have deep experience in precision oncology trials
Seasoned project leads, CRA and CRCs with prior global clinical trial experience